EN DE
Watch Merit Medical Systems Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Merit Medical Systems Inc (MMSI) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Merit Medical Systems Inc stock $89.92, price $87.23, upside +3.1%, quality 62 out of 100. Rating: fairly valued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

MM Merit Medical Systems Inc logo Some data Nov 6, 2026

Merit Medical Systems Inc

MMSI · US
Fairly valued, sideways

The stock costs about what our calculation considers fair.

Quality 62/100
Healthy Growth (revenue 5y +9.5 %/yr in USD)
Low debt
Generates free cash flow
Upbeat coverage
Fair value $89.92 · Fairly valued (+3.1%)
Thin margins · 9.2% net margin (TTM)
Mixed vs. peers (7/14)
Moderate moat 51/100 · thin data
Insiders bought $99,186 (6M) · sold $2.5M
Some data
Quality growth
Watch Merit Medical Systems Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$110.29 $51.68 Fair Value $89.92 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range $51.68 – $110.29 · fair‑value band $63.68 – $116.18 · the $87.23 price screens below the $89.92 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 6, 2026.

Follow Merit Medical Systems in your weekly email

Every Wednesday you see whether Merit Medical Systems is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States, China, Japan, Germany, France, the United Kingdom, and internationally.

Show moreShow less

It operates through two segments, Cardiovascular and Endoscopy.

The company offers micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention products comprising angiography, drainage, delivery systems, and embolotherapy products; oncology products, such as soft tissue biopsy products and accessories; cardiac intervention products consisting of cardiac access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention products; and spine products, including vertebral augmentation, radiofrequency ablation, and bone biopsy systems.

It also provides custom procedural solutions, including critical care products, syringes, manifold kits, and trays and packs; coating services for medical tubes and wires; and sensor components for microelectromechanical systems.

In addition, the company offers gastroenterology products, such as esophageal stents, cryoballoon and inflation devices, gauges, and balloon dilators; pulmonary products consisting of laser-cut tracheobronchial stents, and over-the-wire and direct visualization delivery systems; and kits and accessories for endoscopy and bronchoscopy procedures.

It sells its products to hospitals, alternate site-based physicians, technicians, and nurses through direct sales force, independent distributors, original equipment manufacturer partners, and custom procedure tray manufacturers.

The company exports its products to Canada, Western Europe, Australia, Brazil, Malaysia, South Korea, the United Arab Emirates, India, New Zealand, and South Africa. Merit Medical Systems, Inc. was incorporated in 1987 and is headquartered in South Jordan, Utah.

Stock analysis

Merit Medical Systems Inc (MMSI) currently trades at $87.23, while our model-based Fair Value estimate is $89.92, so the stock looks roughly fairly valued today (gap 3.0%).

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of $75.10 per share, and 4 of the 24 models we run sit above the $87.23 price.

Bear case: the Economic Profit group reads lowest at $23.70, and 20 of the 24 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $63.68 (bear) to $116.18 (bull), the price of $87.23 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 62/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Merit Medical Systems Inc reported revenue of $1.5B in FY2025 versus $1.1B in FY2021, a compound +9.0%/yr. Reported net income was $128M in FY2025, compounding +27.6%/yr from FY2021.

Key figures

Market cap $5.2B Mid · P/E ratio 32.7 · P/S ratio 3.32 · EPS (TTM) $2.67 · Net margin 9.2% · Return on equity 9.2% · Return on assets (EBIT) 5.5% (5-year average) · Operating margin 14.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 51 out of 100 (low confidence).

What moves the price

The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.

The share trades about 7% below its 52-week high and 45% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at 3%, MMSI screens cheaper than that median.

Fair Value models

Bear $63.68 Fair Value $89.92 Bull $116.18
Price $87.23 · Upside +3.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($2.28 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $49.91 $98.96 $189.68 76
EPV $18.91 $23.07 $26.77 74
Growth DCF $49.46 $94.63 $176.88 74
All 24 models by family
DCF Models
FCF DCF $49.91 $98.96 $189.68 76
Owner Earnings $36.56 $73.66 $142.24 72
5Y Revenue Exit $31.35 $55.90 $88.89 71
5Y EBITDA Exit $48.18 $91.07 $145.39 73
5Y P/E Exit $34.85 $63.21 $95.64 69
10Y Revenue Exit $35.91 $61.80 $101.06 65
10Y EBITDA Exit $48.39 $88.34 $150.04 66
10Y P/E Exit $39.31 $67.31 $106.91 62
Earnings-Based
Graham-Dodd $14.63 $71.12 $97.97 64
Lynch FV $19.05 $27.22 $35.39 61
PEG = 1.0 $19.05 $27.22 $35.39 57
EPV $18.91 $23.07 $26.77 74
Multiples
P/E Multiple $35.51 $47.34 $59.18 63
P/S Multiple $27.44 $36.58 $45.73 58
P/B Multiple $30.51 $40.68 $50.85 55
EV/EBIT $31.84 $44.96 $58.09 65
EV/EBITDA $48.57 $67.27 $85.97 67
EV/Revenue $20.57 $32.61 $44.65 53
Asset-Based
NCAV (Graham) $4.52 $6.06 $9.04 54
Growth DCF
Growth DCF $49.46 $94.63 $176.88 74
Rev-Margin DCF $31.35 $55.56 $87.35 71
Economic Profit
Residual Income $22.50 $24.32 $28.42 71
ROIC Compounder $18.91 $23.07 $27.13 72
Growth Earnings
Growth-Adj P/E $30.33 $43.33 $56.32 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 62/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 41
How much profit the company makes from its sales and capital
Quality Growth 55
Are margins and returns getting better?
Cashflow 74
Do the profits arrive as real cash?
Financial strength 74
Debt, balance sheet and risk of trouble
Investment 46
Does it invest with discipline instead of growing at any price?
Low Volatility 82
How calm the share price moves, does not count
Price momentum 56
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 57
Distance to the 52-week high, does not count
New shares 81
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director bought shares worth $99,186, on May 11, 2026. Over the same period, one person sold shares worth $2.5M.

  • SaleNeil W. PetersonCHIEF OPERATING OFFICER3× since Jan 6, 2026: 33,949 shares, avg. $86.94$3.0MAug 24, 2026
  • BuyChristian Adam SmithChief Commercial Officer1,626 shares at $61.00$99,186May 11, 2026
  • BuyBrian G. LloydCHIEF LEGAL OFFICER, SECRETARY2,000 shares at $62.63$125,260May 7, 2026
  • SaleLynne N. WardDirector5,000 shares at $62.61$313,050May 7, 2026
  • BuyMartha Goldberg AronsonPresident and CEO, Director2,000 shares at $60.44$120,880May 6, 2026
  • BuyRaul Parra Jr.CFO AND TREASURER1,500 shares at $61.01$91,515May 6, 2026
  • BuyMichel J. VoigtCHIEF HUMAN RESOURCES OFFICER2,250 shares at $60.65$136,463May 5, 2026
  • SaleFred P. LampropoulosExecutive Chairman, Director4× since Nov 18, 2025: 60,000 shares, avg. $86.50$5.2MNov 25, 2025

Plus 14 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 80/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+11.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.5%
Start year 2020 (pandemic). Over 10 years: +10.8% a year
Revenue growth 36 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.4%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+35.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+35.2%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.35.2% vs 14.9%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.0% → 12%
Pace: the 5-year rate starts in 2020 (pandemic)

Growth Forecast

A lot of optimism in the price
The price assumes about as much growth as the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+10.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+6.0%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +8.3% a year for the price and +3.5% for the forecasts.
Forecast 2026 (sales)+8.2%
Forecast 2027 (sales)+6.2%
Projected 2028 (sales)+5.7%
Projected 2029 (sales)+5.2%
Projected 2030 (sales)+4.6%

Watch MMSI, get fair value alerts →

Recent news

News mood ⓘNews mood, the average tone of recent news (96 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
Note from the team Oct 11, 2026
AI conclusion: Merit Medical shows strength in multi-year efficiency programs that lifted operating margins in oncology and endoscopy, yet its main weakness remains thin evidence of durable signals and margins that are not exceptional versus peers.
Main risk: Tariff costs built into guidance and reimbursement risks for newer platforms threaten to limit the impact of operating margin gains in established areas such as oncology and endoscopy.
Merit Medical keeps advancing multi-year efficiency programs that have already lifted operating margins. These improvements now face tariff costs built into guidance and reimbursement risks for newer platforms. Will the margin gains plus established areas like oncology and endoscopy more than offset those pressures, or will external factors cap the benefits?
Join the discussion →

Compare Merit Medical Systems Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks

Beats the industry median on 7/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 62 · Above median
Fair Value upside +3.1% · Above median
Profitability
Return on equity (12 months) 9.2% · Above median
Return on assets 4.8% · Above median
Net margin (12 months) 9.2% · Above median
Operating margin (12 months) 14.5% · Above median
Growth and dividend
Revenue growth (quarter YoY) 9.5% · Above median
Balance sheet
Debt / equity 0.46× · Highest 25%

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/E (12 months) 32.7× · Pricier than median
P/B 3.30× · Pricier than median
P/S (12 months) 3.32× · Pricier than median
Price / free cash flow (fiscal year) 24.3× · Pricier than median
EV/EBITDA 16.3× · Pricier than median
PEG 1.56× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)37 · sector 25
FUTURE (revenue growth)48 · sector 40
PAST (return on equity)37 · sector 31
HEALTH (low debt)77 · sector 96
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Solventum Corporation SOLV $90.38 $131.06 +45% vs MMSI
EssilorLuxottica Société anonyme EL €193.80 €196.22 +1% vs MMSI
Intuitive Surgical, Inc ISRG $452.80 $353.90 −22% vs MMSI
Medline Inc MDLN $39.64 $28.59 −28% vs MMSI
Alcon Inc ALC CHF 61.30 CHF 33.91 −45% vs MMSI
Straumann Holding STMN CHF 104.50 CHF 45.50 −56% vs MMSI
Becton, Dickinson and Company BDX $211.88 $82.34 −61% vs MMSI
West Pharmaceutical Services, Inc WST $399.81 $139.22 −65% vs MMSI
Sartorius Stedim Biotech S.A DIM €225.80 €54.82 −76% vs MMSI
Sartorius Aktiengesellschaft SRT €227.00 €42.50 −81% vs MMSI

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Merit Medical Systems Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Merit Medical Systems Inc Fair Value". https://www.fairvalue-calculator.com/stock/MMSI

Frequently asked questions

Is Merit Medical Systems Inc (MMSI) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $89.92 versus a price of $87.23, about +3% upside (fairly valued).
What is the fair value of MMSI?
Our model-based fair value for Merit Medical Systems Inc is $89.92 (as of Nov 6, 2026), built from audited fundamentals. The current price: $87.23.
What is the quality score of MMSI?
Merit Medical Systems Inc has a Quality Score of 62/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Merit Medical Systems Inc (MMSI)?
Our model-based price target is the fair value of $89.92 (as of Nov 6, 2026) from 24 valuation models. Cautious scenario $63.68, optimistic scenario $116.18. It is a calculation from audited fundamentals, not an analyst target.
What is the Merit Medical Systems Inc stock forecast for 2026?
Our models put fair value at $89.92, about +3% upside versus a price of $87.23 (fairly valued). Cautious scenario $63.68, optimistic scenario $116.18. The calculation is refreshed regularly with new filings.
What is the revenue of Merit Medical Systems Inc (MMSI)?
Merit Medical Systems Inc reported trailing-twelve-month revenue of about $1.6B (latest available figure, as of Nov 6, 2026).
What growth is priced into Merit Medical Systems Inc (MMSI)?
For today's price to be fair in a discounted-cash-flow model, Merit Medical Systems Inc would have to grow free cash flow by +10.8 % per year for five years (discount rate 8.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +9.5 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of MMSI use?
Our models discount Merit Medical Systems Inc at 8.5 %: a base by market capitalisation (mid), damped by beta 0.51, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Merit Medical Systems Inc that is +10.8 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.5 %) and the same formula as our fair value.
How much growth has Merit Medical Systems Inc (MMSI) delivered so far?
Over the past 5 years revenue at Merit Medical Systems Inc grew +9.5 % a year. The price currently implies free-cash-flow growth of +10.8 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Merit Medical Systems Inc (MMSI) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Merit Medical Systems Inc (+10.8 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Merit Medical Systems Inc (MMSI)?
The free-cash-flow yield on the price is 4.12 %: that much free cash flow Merit Medical Systems Inc produces per unit of market value. When it exceeds the discount rate of our models (8.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Merit Medical Systems Inc (MMSI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Merit Medical Systems Inc it is $89.92 per share (as of Nov 6, 2026), against a price of $87.23. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Merit Medical Systems Inc stock overvalued or undervalued in 2026?
As of Nov 6, 2026, MMSI trades below its calculated fair value: price $87.23, fair value $89.92, a gap of about +3% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MMSI?
No. The price is what the market pays today ($87.23); the fair value is what the company's own numbers justify ($89.92). For Merit Medical Systems Inc the two are $2.69 per share apart. That gap is exactly why we show both numbers side by side.
How much is Merit Medical Systems Inc worth?
The market values Merit Medical Systems Inc at about $5.2B (market capitalisation, as of Nov 6, 2026). Per share that is $87.23; our models calculate a fair value of $89.92 per share.
What do the bullish and bearish scenarios say about MMSI?
Our models span a range for Merit Medical Systems Inc: cautious scenario $63.68, base $89.92, optimistic $116.18 per share (as of Nov 6, 2026, price $87.23). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of MMSI?
Merit Medical Systems Inc trades at a price-to-earnings ratio of 32.7 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $89.92 is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2016 to 2025), reported earnings: 59.1. Other multiples: PEG 1.6, P/B 3.3, P/S 3.3, EV/EBITDA 16.3.
What is the PEG ratio of MMSI?
The PEG ratio of Merit Medical Systems Inc is 1.56 (P/E divided by earnings growth, as of Nov 6, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Merit Medical Systems Inc (MMSI)?
Balance-sheet figures for Merit Medical Systems Inc (as of Nov 6, 2026): return on equity 9.2%, debt of 0.46 per unit of equity. They feed the Quality Score of 62/100, which measures business quality independently of the share price.
How far is MMSI from its 52-week high?
Merit Medical Systems Inc trades at $87.23, about 7% below its 52-week high of $94.20 and 45% above the low of $60.31 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $89.92 is for.
Which stocks are comparable to Merit Medical Systems Inc?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Merit Medical Systems Inc stock attractive at the current price?
The data as of Nov 6, 2026: price $87.23, calculated fair value $89.92 (+3%), Quality Score 62/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MMSI calculated?
We run Merit Medical Systems Inc through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $89.92 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Merit Medical Systems Inc currently trades 3% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Merit Medical Systems Inc (MMSI)?
The closing price on Nov 6, 2026 was $87.23. Our model-based fair value is $89.92, about +3% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Merit Medical Systems Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range ($63.68 to $116.18) leaves room in how you read the outcome.
Where does the earnings growth of Merit Medical Systems Inc (MMSI) come from?
Earnings per share at Merit Medical Systems Inc grew +16.1 % a year from 2014 to 2025. Broken into its drivers: revenue per share +7.1 %, EBIT margin +5.7 %, tax rate +0.5 %, residual (interest, one-offs) +2.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Merit Medical Systems Inc

How large is the market capitalisation of Merit Medical Systems Inc (MMSI)?
The market capitalisation of Merit Medical Systems Inc is $5.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Merit Medical Systems Inc (MMSI)?
The price-to-sales ratio of Merit Medical Systems Inc is 3.32 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Merit Medical Systems Inc (MMSI)?
Earnings per share at Merit Medical Systems Inc are $2.67 (price ÷ EPS = P/E 32.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Merit Medical Systems Inc (MMSI)?
The net margin of Merit Medical Systems Inc is 9.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Merit Medical Systems Inc (MMSI)?
The return on equity (ROE) of Merit Medical Systems Inc is 9.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Merit Medical Systems Inc (MMSI)?
On an EBIT basis the return on assets of Merit Medical Systems Inc is 5.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Merit Medical Systems Inc (MMSI)?
The operating margin of Merit Medical Systems Inc is 14.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Merit Medical Systems Inc (MMSI)?
Revenue at Merit Medical Systems Inc is growing +9.5% versus a year earlier (3y avg +9.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Merit Medical Systems Inc (MMSI)?
Earnings per share at Merit Medical Systems Inc are growing +20.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Merit Medical Systems Inc (MMSI) carry?
The net debt of Merit Medical Systems Inc is $450M (fiscal year 2025, ≈ 2.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Merit Medical Systems Inc in the live analysis

One click puts Merit Medical Systems Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.